Showing all 6 results
Tirzepatide was originally developed to treat type 2 diabetes, but it has also demonstrated protective effects on the cardiovascular system. It is a synthetic analog of gastric inhibitory polypeptide (GIP) that also mimics the actions of glucagon-like peptide-1 (GLP-1). This dual mechanism helps reduce blood glucose levels, enhance insulin sensitivity, and promote a sense of satiety.
Tirzepatide is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) activity. This dual mechanism enables it to reduce blood glucose levels, enhance insulin sensitivity, and promote satiety. Originally developed for the treatment of type 2 diabetes, Tirzepatide has also demonstrated cardiovascular protective effects.
Tirzepatide is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) activity. This dual mechanism enables it to reduce blood glucose levels, enhance insulin sensitivity, and promote satiety. Originally developed for the treatment of type 2 diabetes, Tirzepatide has also demonstrated cardiovascular protective effects.
Tirzepatide is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) activity. This dual mechanism enables it to reduce blood glucose levels, enhance insulin sensitivity, and promote satiety. Originally developed for the treatment of type 2 diabetes, Tirzepatide has also demonstrated cardiovascular protective effects.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose metabolism. As a GLP-1 receptor agonist, Semaglutide mimics the effects of endogenous GLP-1, promoting insulin secretion and suppressing glucagon release in a glucose-dependent manner—a mechanism that helps lower blood sugar without causing hypoglycemia.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose metabolism. As a GLP-1 receptor agonist, Semaglutide mimics the effects of endogenous GLP-1, promoting insulin secretion and suppressing glucagon release in a glucose-dependent manner—a mechanism that helps lower blood sugar without causing hypoglycemia.
